drugset / Trial / NCT03954236
Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
Phase 2
Active not recruiting
24 enrolled
Memorial Sloan Kettering Cancer Center
Hackensack Meridian Health · collabIncyte Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the safety and effects of ruxolitinib 1.5% cream with those of standard moisturizers in people with non-sclerotic chronic cutaneous GVHD.
Timeline
- Start
- 2019-05-14
- Primary completion
- 2027-02-06
- Completion
- 2027-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 1.5 % | Topical |